A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis
Participants must be 18 to 90 years of age inclusive, at the time of signing the informed consent.
Diagnosis of ATTR-CM; disease defining examination, i.e., Single Photon Emission Computed Tomography (SPECT) or SPECT/Computed Tomography (CT) or biopsy, within 24 months prior to Visit 1 (V1).
Participants must currently be treated with tafamidis and have used tafamidis for at least the previous 3 months prior to V1 and have adhered to tafamidis therapy.
New York Heart Association (NYHA) class ≤ II at V1.
Estimate glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73m\^2 at V1.
N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) \> 300 and ≤ 7000 pg/mL at V1.
You may not be if
Prior liver or heart transplantation or planned within the next 12 months.
Current or planned use of ventricular assist device.
Active cancer or other disease that decreases the life expectancy to less than one year.
Heart failure due to ischemic heart disease.
Myocardial infarction, cardiovascular (CV) surgery, or unstable angina within the last 90 days prior to V1.
Confirmed diagnosis of light-chain amyloidosis.
Dialysis or severe renal impairment as reflected by Urinary Albumin Creatinine Ratio (UACR) \> 300 mg/g at V1.
Major surgery within 90 days prior to V1.
Recent initiation of Sodium-Glucose-Cotransporter-2 inhibitors (SGLT2i) within 3 months before V1.
Initiation of treatment with a diuretic or increase in diuretic dose within 3 months before V1.
Treatment with calcium channel blockers (e.g., verapamil, diltiazem) or digitalis.
Recent CV hospitalization within 3 months before V1.
Known hypersensitivity to acoramidis or to any of the excipients.
A condition that, as judged by the investigator, would preclude compliance with the study protocol, such as a history of substance abuse, alcoholism, or a psychiatric condition.
Known or suspected liver disorder and bile secretion/flow (cholestasis, also history of it).
Abnormal liver function tests at V1, defined as ALT (GPT) or AST (GOT) ≥ 3 x ULN or total bilirubin ≥ 3 x ULN at V1.